|
Publication |
|
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. Papadopoulos D, Ha SA, Fleischhauer D, Uhl L, Russell TJ, Mikicic I, Schneider K, Brem A, Valanju OR, Cossa G, Gallant P, Schuelein-Voelk C, Maric HM, Beli P, Büchel G, Vos SM, Eilers M. Mol Cell. 2024 Jun 6;84(11):2070-2086.e20. doi: 10.1016/j.molcel.2024.04.007. Epub 2024 May 3.
|
|
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration. Kosinski J, Sechi A, Hain J, Villwock S, Ha SA, Hauschulz M, Rose M, Steib F, Ortiz-Brüchle N, Heij L, Maas SL, van der Vorst EPC, Knoesel T, Altendorf-Hofmann A, Simon R, Sauter G, Bednarsch J, Jonigk D, Dahl E. Mol Oncol. 2024 Jun;18(6):1486-1509. doi: 10.1002/1878-0261.13609. Epub 2024 Feb 20.
|
|
Beyond gene expression: how MYC relieves transcription stress. Papadopoulos D, Uhl L, Ha SA, Eilers M. Trends Cancer. 2023 Oct;9(10):805-816. doi: 10.1016/j.trecan.2023.06.008. Epub 2023 Jul 7.
|
MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Papadopoulos D, Solvie D, Baluapuri A, Endres T, Ha SA, Herold S, Kalb J, Giansanti C, Schülein-Völk C, Ade CP, Schneider C, Gaballa A, Vos S, Fischer U, Dobbelstein M, Wolf E, Eilers M. Mol Cell. 2022 Jan 6;82(1):159-176.e12. doi: 10.1016/j.molcel.2021.11.002. Epub 2021 Nov 29.
|
|
| | Last update Publications 11.05.2024 |
|